NCT00145301已完成3 期
A 52-week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid and Celecoxib 200 mg od in Patients With Primary Osteoarthritis of Hip, Knee, Hand or Spine
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 3,036
- 试验地点
- 2
- 主要终点
- To show that either regimen of lumiracoxib (100mg od or 100mg bid) is not inferior to celecoxib 200mg od with respect to retention rate at 1 year in pts suffering from primary OA in hip, knee, hand or spine.
研究概览
简要总结
This trial will compare the retention on treatment (based on the rate of patients staying on treatment for 1 year) of patients suffering from primary osteoarthritis using two different doses of lumiracoxib (100 mg od or 100 mg bid) or using celecoxib (200 mg od)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Primary osteoarthritis in the hip, knee, hand, or spine
- •Requiring NSAID therapy
排除标准
- •Secondary OA with history and/ or any evidence of the following diseases: rheumatoid arthritis, uncontrolled gout, inflammatory joint disease, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary osteochondromatosis, heritable disorders (e.g. hypermobility), collagen gene mutations, primary fibromyalgia (secondary fibromyalgia is allowed if in the opinion of the investigator it will not interfere with the patient's OA pain assessment), and systemic lupus erythematosus
- •History and/ or any evidence of the following diseases in the target joint: septic arthritis, gout, recurrent episodes of pseudogout, Paget's disease of the bone, and articular fracture. If the patient has history of these conditions, then patient should only be excluded if the target joint is affected.
- •History of severe adverse reactions of any kind under lumiracoxib or celecoxib treatment.
- •Other protocol-defined inclusion/exclusion criteria may apply.
结局指标
主要结局
To show that either regimen of lumiracoxib (100mg od or 100mg bid) is not inferior to celecoxib 200mg od with respect to retention rate at 1 year in pts suffering from primary OA in hip, knee, hand or spine.
次要结局
- Safety & tolerability of pts using lumiracoxib vs pts using celecoxib
- Efficacy of lumiracoxib vs celecoxib with respect to Patient's assessment of OA pain, Patient's global assessment of disease activity, and Physician's global assessment of disease activity
- To compare reasons for discontinuation from treatment with lumiracoxib vs treatment with celecoxib
- To validate the psychometric properties of the Short Arthritis assessment Scale (SAS) by analyzing pt reported outcomes collected in this study
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and TransplantationLung PreservationNCT01630434TransMedics320
已完成
3 期
Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese PatientsChronic Obstructive Pulmonary DiseaseNCT01119937Novartis Pharmaceuticals211
终止
4 期
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMSRelapsing Remitting Multiple SclerosisNCT00202995Teva Branded Pharmaceutical Products R&D, Inc.91
招募中
不适用
Clinical Trial to Compare Two Surgical Approaches to the CochleaCochlear ImplantsHearing Loss, SensorineuralNCT06453343Radboud University Medical Center50
已完成
3 期
Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)NCT01285492Novartis Pharmaceuticals160